Supplementary material to article by D. Roblin et al. "Topical TrkA Kinase Inhibitor CT327 is an Effective, Novel Therapy for the Treatment of Pruritus due to Psoriasis: Results from In vitro and Tissue Experimental Studies, and Efficacy and Safety of CT327 in a Phase 2b, Randomised, Double-blind, Vehicle-controlled Clinical Trial in Patients with Psoriasis"

Table SIV. List of treatment emergent adverse events (full analysis set). Number (%) of subjects

	CT327 0.05% n=40	CT327 0.1% n=40	CT327 0.5% n=40	CT327 Overall <i>n</i> =120	Vehicle n=40
Total treatment emergent adverse events*	13 (33)	17 (43)	22 (55)	52 (53)	21 (53)
Nasopharyngitis	1 (3)	0	3 (8)	4(3)	1 (3)
Headache	2 (5)	2 (5)	1 (3)	5 (4)	0
Diarrhoea	0	1 (3)	2 (5)	3 (3)	1 (3)
Psoriasis	0	0	2 (5)	2(2)	1 (3)
Upper respiratory tract infection	0	0	0	0	2 (5)
Pruritus	4(10)	2 (5)	3 (7.5)	9 (7.5)	6 (15)
Back pain	0	2 (5)	0	2(2)	0
Fatigue	2 (5)	0	0	2(2)	0
Cough	2 (5)	0	0	2(2)	0

^{*}Counting is by subject, not event.